Jamie A. Donadio has served as acting Chief Financial Officer of Renibus since January 2022. Mr. Donadio holds over 20 years of finance and accounting experience, including 19 years at publicly held biopharmaceutical companies from development stage through commercialization. Most recently, Mr. Donadio served as Chief Financial Officer at BioTheryX, where he helped the Company raise a $100 million Series E financing round and prepare for a potential IPO. Prior to BioTheryX, Mr. Donadio served as Chief Financial Officer at Mirati Therapeutics, Inc. a publicly traded, targeted oncology company where he helped the Company raise over $800 million through public equity offerings. At Mirati, Mr. Donadio also played a key role in the Company’s reorganization and relocation to San Diego, as well as its Nasdaq listing and subsequent growth. Prior to Mirati, Mr. Donadio held roles of increasing responsibility at Amylin Pharmaceuticals, Inc. most recently serving as Senior Director of Finance. Prior to Amylin, Mr. Donadio held roles at Novatel Wireless, Inc. and Ernst & Young LLP. Mr. Donadio holds a B.S. in Accounting from Babson College and is a certified public accountant (inactive) in the State of California.